Invention Grant
- Patent Title: Stem cells for modeling type 2 diabetes
-
Application No.: US14974785Application Date: 2015-12-18
-
Publication No.: US10196613B2Publication Date: 2019-02-05
- Inventor: Guochun Gong , Ka-Man Venus Lai , David M. Valenzuela
- Applicant: Regeneron Pharmaceuticals, Inc.
- Applicant Address: US NY Tarrytown
- Assignee: Regeneron Pharmaceuticals, Inc.
- Current Assignee: Regeneron Pharmaceuticals, Inc.
- Current Assignee Address: US NY Tarrytown
- Agency: Alston & Bird LLP
- Agent Yongjin Choi
- Main IPC: C12N5/074
- IPC: C12N5/074 ; A01K67/027 ; C12N5/071 ; G01N33/50 ; G01N33/74 ; A61K35/39 ; A61K35/545 ; C12N15/10 ; C12N15/90 ; C12N15/11
Abstract:
The invention provides stem cell derived beta-pancreatic cells and animal models of T2D in which cells have been grafted. The stem cells bear a mutated form of SLC30A8 conferring protection or susceptibility to T2D. The cells and animal models can be used for drug screening as well as to provide insights into the mechanism of T2D and potentially new therapeutic and diagnostic targets.
Public/Granted literature
- US20160177273A1 STEM CELLS FOR MODELING TYPE 2 DIABETES Public/Granted day:2016-06-23
Information query
